
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
Roundtable Discussionover 26 years ago
Selected Abstractsover 26 years ago
Continuing Medical/Pharmacy Education Quizover 26 years ago
Bibliography





